Gene rearrangement and Chernobyl related thyroid cancers by Santoro, M et al.
The accident at the Chernobyl nuclear power plant on 26 April
1986 resulted in the population of Southern Belarus and Northern
Ukraine being exposed to radioactive fallout which contained
substantial amounts of radioactive iodine. It became apparent in
1992 that there was an increase in childhood thyroid carcinoma
(Baverstock et al, 1992; Kazakov et al, 1992). Thyroid carcinoma
in children is usually rare (of the order of 0.3–1.3 million–1 year–1;
Parkin et al, 1988). The first reaction to the increase in thyroid
carcinoma was one of surprise, due largely to the reported size of
the increase and the short latent period. However, a number of
published studies support the view that the tumours are causally
related to exposure from Chernobyl (Likhtarev et al, 1995;
Williams, 1996; Jacob et al, 1998).
Two morphologically distinct types of differentiated carcinoma
derive from the thyroid follicular cell, papillary carcinoma and
follicular carcinoma. The two different types exhibit not only
different morphology but also different biological behaviour and
are associated with mutations in different oncogenes; papillary
carcinoma with rearrangement of either the RET or trk oncogenes
(Greco et al, 1992; Santoro et al, 1992) and follicular carcinoma
with mutation of the ras oncogene (Lemoine et al, 1989).
Mutations of exon 10 of the thyroid stimulating hormone (TSH)
receptor have been particularly associated with a specific type of
benign thyroid tumour, the hot nodule (Parma et al, 1995), but
there have been reports of TSH receptor mutation in follicular
carcinoma (Russo et al, 1995). The p53 oncogene is commonly
mutated in many different types of carcinoma; in thyroid carci-
noma it is associated with anaplastic carcinoma, rather than the
differentiated types of thyroid carcinoma (Ito et al, 1992).
The majority of the rise in post-Chernobyl thyroid carcinoma
incidence has been due to an increase in papillary carcinoma.
However, papillary carcinoma in children can be subdivided into
three main subtypes, solid/follicular, classical and diffuse scleros-
ing variant (Harach and Williams, 1995). The morphological char-
acteristics of any tumour result from the integration of the
molecular biological changes involved in the genesis of that
tumour. In this study we have therefore correlated the morpho-
logical findings with molecular biological analysis of mutation in
four oncogenes associated with thyroid carcinogenesis (RET, ras,
p53 and exon 10 of the TSH receptor).
METHODS
Verification of pathology
All material was provided by the Institute of Pathology in Minsk
and the Institute of Endocrinology and Metabolism in Kiev.
Sections from representative paraffin blocks from each of the
cases examined were stained with haematoxylin and eosin (H&E),
and with a standard immunocytochemical techique for calcitonin
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Correspondence to: GA Thomasand thyroglobulin. Papillary carcinomas were classified as either
solid/follicular, classical or diffuse sclerosing variant based on
their dominant morphological component, using definitions given
in our previous study of the morphology of childhood thyroid
cancer in England and Wales (Harach and Williams, 1995). Where
possible, frozen sections of unfixed material for DNA and RNA
extraction were also examined to determine the presence and
amount of tumour epithelium in the frozen material.
A total of 132 cases were used for this molecular biological
study. Fresh material was available in 50 cases; analyses were
performed on paraffin sections for the remaining 82 cases. All
cases were operated in Minsk or Kiev between 1990 and 1996.
Serial paraffin sections were cut at one centre and circulated to the
other centres for extraction and analysis of the various oncogenes.
Paraffin material was only available from those cases operated in
1990–1994, fresh material was available from cases operated in
1995 and 1996. DNA and RNA from fresh material was extracted
at one centre using a standard Trizol™ protocol. Aliquots were
distributed to other centres for analysis of RET rearrangement,
mutation of the TSH receptor, Ki, Ha, N ras and p53 oncogenes.
RT-PCR for RET/PTC expression
Reverse transcription and subsequent PCR amplification was
performed on both paraffin and fresh material as previously
reported. The sequence of the forward primers used were: for
RET/PTC1: 5¢-ATTGTCATCTCGCCGTTC-3¢, specific for the H4
gene, and for RET/PTC3: 5¢-AAGCAAACCTGCCAGTGG-3¢,
specific for the ele1 gene. The sequence of the reverse primer was:
5¢-TGCTTCAGGACGTTGAAC-3¢, specific for RET tyrosine
kinase. One microgram of RNA was reverse transcribed using the
reverse primer and, following the addition of the forward primer,
subjected to 40 cycles of PCR (94°C for 30 min, 55°C for 2 min
and 72°C for 2 min). The product of the reaction was analysed on a
2% agarose gel and hybridized with a probe for the RET tyrosine-
kinase domain. The HPRT specific primers were: 5¢-CCTGCTG-
GATTACATCAAAGCACTG-3¢ (forward), corresponding to the
nucleotides 316–340 of the third exon of the human gene; 
5¢-CCTGAAGTATTCATTATAGTCTCAAGG-3¢ (reverse) corres-
ponding to the nucleotides 685–661 of the eighth exon of the
human gene.
RT-PCR method for detecting expression of the RET
tyrosine kinase domain (TK) and extracellular domain
(EC)
The reverse transcription reaction was performed on 1 mg of RNA.
The RT reaction was performed in a final volume of 25 ml
containing 0.1 optical density units of random hexamers
(Pharmacia P(N)6), 2.5 ml of 103 RT buffer (13RT 50 mM
Tris–HCl (pH 8.3), 50 mM potassium chloride (KCl), 4 mM dithio-
threitol (DTT), 10 mM magnesium chloride (MgCl2)), 2.5 ml of 
10 mM dNTPs, 1 unit ml–1 RNasin and 200 units ml–1 of super RT
and incubated at 41°C for 60 min. The reaction was terminated at
95°C for 5 min. Fifteen microlitres of the reaction mixture were
used for PCR amplification with primers 5¢-CACCGGATGGA-
GAGGCCAGACAACTGCAGC-3¢ and 5¢-ACCGGCCTTTTGT-
CCGGCTC-3¢  (TK), and5¢-GTGCAGTTCTTGTGCCCCAAC-
ATCAG-3¢ and 5¢-CCCAGCGCGTGCTCACCT-3¢ (extracellular) 
in a final volume of 100 ml. Primers for the 3¢ end of the RET
oncogene (TK) corresponded to exon 16, 5¢ upstream and exon 17,
3¢ downstream spanning a 1150 bp intron, primers for the extracel-
lular domain were designed to span intron 4, giving a product from
RNA of 106 bp. PCR reactions consisted of 35 cycles of ampli-
fication at 95°C for 30 s, 50°C for 30 s and 72°C for 1 min.
Precautions were taken to prevent PCR contamination. Parallel
reagent negative controls were run with all samples to exclude
generalized PCR contamination. 15 ml of each PCR reaction was
run on a 2% agarose gel together with ØX markers. The specificity
of the PCR product was confirmed by Southern blotting using a
probe specific for 3¢ region of the RET gene.
S6 ribosomal mRNA was used as a reporter target for amplifica-
tion to monitor the presence of RNA; a negative amplification
result indicated RNA degradation. The primers 5¢-AATCCG-
CAAACGTTTCAATCTCT-3¢ and 5¢-TGAATCTTGGGTGCTT-
TGGTCCTA-3¢ were chosen in different exons to generate a 
106 bp PCR product from mRNA, readily distinguished from 
S6 genomic amplification which would result in a PCR product of
1826 bp. Amplification was performed for 35 cycles using the
same conditions as for RET TK and extracellular PCRs. RNA
extracted from the SHSY neuroblastoma cell line, which expresses
c-RET, was used as a positive control. RNA extracted from the
293 kidney cell line, which does not express c-RET was used as a
negative control, together with conventional no template controls.
Both cell lines were kindly provided by Professor Bruce Ponder
(Human Cancer Genetics Group, University of Cambridge).
TSH receptor mutation
Paraffin sections were washed in xylene and ethanol. After
vacuum drying of the pellet, proteinase K (1 mg ml–1) in 50 mM
Tris buffer was added at 55°C for 2 h and then at 37°C overnight.
After heating the sample for 10 min at 100°C to inactivate the
proteinase K, the quality of the DNA was checked on a 0.8%
agarose gel, which showed the presence of high molecular weight
DNA after ethidium bromide staining.
Two fragments (bases 2078–2664 and bases 1273–2340) of the
TSH receptor gene were amplified by PCR and subjected to
double-strand direct sequencing. The antisense primer was
biotinylated in each case. The PCR reaction was performed in a
final volume of 100 ml, containing 2 ml of DNA, 50 mM KCl, 
10 mM Tris–HCl pH 8.3, 1.5 mM MgCl2, 0.01% gelatin, 0.2 mM
dNTP, 5 U Taq polymerase (Boehringer Mannheim, Germany) and
200 nM of each primer. Samples were denatured at 93°C for 2 min
for the first pair of primers followed by 50 cycles of 93°C for 1
min, 54°C for 1 min and 72°C for 2 min 30 s. A final extension of
6 min at 72°C was performed. The protocol for the second pair of
primers differed by using an annealing temperature of 50°C rather
than 53°C. PCR products were visualized by ethidium bromide
staining on agarose gels; a strong band of the expected size 
(600 bp) was observed by using the first pair of primers, while a
faint band of the expected size (1000 bp) was observed with the
second pair of primers. PCR negative control (water instead of
DNA template) and the material obtained by using a paraffin block
devoid of tissue did not show any amplification. Mutations in the
TSH receptor amplimers were identified by single-strand confor-
mation polymorphism (SSCP), and confirmed by sequencing.
For DNA from frozen specimens, four fragments of the TSH
receptor gene were amplified by PCR and subjected to double-
strand direct sequencing. The fragments and the primers used
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CCC AAT TAA CCT CAG G-3¢; reverse primer 5¢-T7 GCT TCC
AAT TTC CTC TCC AC-3¢; fragment B, residues 430–537
forward primer 5¢-T7 TTC GTT AGT CTG CTG GCT C-3¢,
reverse primer 5¢-M13D CAA CCA TGA TGG CAC ATG-3¢;
fragment C: residues 526–646, forward primer 5¢-M13D CTG
GTA TGC CAT CAC CTT-3¢, reverse primer 5¢-M13R TGA GAG
GCT TGT TCA GAA TT-3¢; fragment D: residues 635–stop
forward primer 5¢-M13D TGT TGA TCT TCA CCG ACT TC-3¢,
reverse primer 5¢-M13R TAA GTT CCC CTA CCA TTG TG-3¢
{M13D, M13R and T7 correspond to universal sequencing
primers (ABI)}. Standard PCR was carried out in a 20 ml volume
containing 200 ng DNA, 50 mM KCl, 10 mM Tris–HCl, pH 8.3,
2m M for fragment A, or 1 mM for fragment B, C and D of MgCl2,
0.01% gelatine, 0.2 mM dNTP, 5 U Taq polymerase (BRL) and 
300 nM for fragment A, 150 nM for fragment B and D or 100 nM
for fragment C of each primer. The annealing temperatures were
61°C for fragment A, 52°C for fragments B, 50°C for C and 48°C
for D respectively. Direct genomic DNA sequencing of both
strands was realized with the dye primer cycle sequencing core kit
(ABI: PN 402070) and mutations searched for by Factura and
Sequence Navigator Software running on an ABI 373 sequencer.
Ras gene mutation
Tumours were microdissected from paraffin-embedded sections.
Following digestion with proteinase K (200 mg ml–1) at 55°C
overnight, PCR was performed in a final volume of 50 ml
containing 50 mM KCl, 10 mM Tris–HCl (pH 8.4), 100 g ml–1
gelatin, 0.2 mM of each primer, 200 mmol of each of dATP, dCTP,
dGTP and dTTP and 2.5 units of Taq polymerase. Exons 1 and 2 of
each of the 3 ras genes (Ha, Ki and N) were amplified. The primer
pairs used and PCR conditions for each gene are given in Table 1.
Following a hot start of 95°C for 3 min, 35 cycles of PCR were
performed consisting of 95°C for 30 s, 48–50°C for 30 s and 72°C
for 1 min followed by a final extension step of 72°C for 6 min. One
of each of the primer pairs was biotinylated; direct sequencing of
the product was carried out using the Dynal and Sequenase 2.0 kits.
p53 mutation analysis
Tissue was microdissected from tumour areas with at least 50%
tumour. Paraffin-embedded tissues were dewaxed with xylene,
washed with ethanol, vacuum-desiccated, resuspended in 200 ml
50 mmol l–1 Tris–HCl pH 8.5, 1 mmol l–1 EDTA, 0.5% Tween-20,
0.2 mg ml–1 proteinase K and incubated at 55°C for at least 3 h.
Proteinase K was inactivated by boiling for 10 min. Two
microlitres of 1:10 dilution were directly used for PCR.
The most conserved regions of the p53 gene comprising exons
5–8 were amplified by PCR as described (Lohmann et al, 1993)
with the exception that exons 6 and 8 were amplified without
nested PCR using only the external primers for the corresponding
exons.
PCR products were diluted 1:2 with 95% formamide, 10 mM
sodium hydroxide (NaOH) 0.05% xylene cyanol, 0.05%
bromophenol blue, denatured at 95°C for 5 min and chilled on ice.
Electrophoresis was performed for each exon under four different
running conditions including those previously found to give
optimal resolution determined from known p53 mutations which
had been identified by direct sequencing (Lohmann et al, 1993). In
brief, 5 ml of denatured PCR product were loaded on a horizontal
8% polyacrylamide gel (30:05) containing 2% glycerine in a 
20 mM MOPS (pH 8.0), 1 mM EDTA running buffer (TGGE
system, Diagen, Düsseldorf, Germany). In addition, elec-
trophoresis was performed in a discontinuous borate-phosphate-
buffer system using 90 mM Tris–borate as running buffer and 8%
polyacrylamide gels containing 2% glycerol prepared in a 90 mM
Tris–phosphate buffer (pH 8.0). Electrophoresis was performed at
15°C and 25°C for exons 5–8 and at 5°C and 15°C for exon 6.
Visualization of DNA was performed by silver staining. Gels were
washed and fixed in 10% ethanol, 0.5% acetic acid for 10 min,
stained with 0.1% AgNO3 for 10 min, washed in distilled water
and developed in 1.5% NaOH, 0.15% formaldehyde and 0.01%
NaBH4.
Analysis of p53 mutation and mutation in the ras oncogenes
were performed on paraffin material only; analysis of RET expres-
sion was performed on frozen material only.
RESULTS
The majority (128/132) of the cases studied were papillary carci-
nomas, three were follicular carcinomas and one was a medullary
carcinoma. The majority (74%) of the papillary carcinomas were of
the solid/follicular subtype, which is the commonest subtype of
papillary carcinoma post-Chernobyl (Bogdanova et al, 1996;
Cherstvoy et al, 1996; Williams, 1996) (Table 2). Of the 106 papil-
lary carcinomas which produced amplifiable RNA and were
analysed for RET rearrangement using rearrangement specific RT-
PCR, 20 were identified as positive for PTC1 and 15 for PTC3; one
other tumour was positive for both PTC1 and PTC3. Examples of
these results are given in Figures 1 and 2. Analysis of the expres-
sion of the extracellular and tyrosine kinase domains was also
performed independently in a different institute in 45 of the 106
cases. Twenty-two of these 45 tumours were positive for expression
of RET tyrosine kinase. No tumour sample showed positivity for
the expression of the RET extracellular domain, suggesting that the
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Table 1 Primer pairs and PCR conditions for amplification of ras oncogenes
Region Sense 5¢–3¢ Antisense 5¢–3¢ Annealing MgCl2
temperature concn.
K ras exon 1 GACTGAATATAAACTTGTGG CTATTGTTGGATCATATTCG 52ºC 1.5 mM
K ras exon 2 AAGTAGTAATTGATGGAGAA CATGTACTGGTCCCTCATT 52ºC 2.5 mM
H ras exon 1 GACGGAATATAAGCTGGTGGTG CTATAGTGGGGTCTGATTCG 48ºC 1.5 mM
H ras exon 2 AGGTGGTCATTGATGGGGAG CATGTACTGGTCCCGCATG 48ºC 1.5 mM
N ras exon 1 ATGACTGAGTACAAACTGGT CTATGGTGGGATCATATTCA 50ºC 1.5 mM
N ras exon 2 AGGTGGTTATAGATGGTGAA CATGTATTGGTCTCTCATG 48ºC 1.5 mMRET tyrosine kinase expression was due to the presence in these
tumours of a RET rearrangement fusing the RET tyrosine kinase
domain of the c-RET gene with an active promoter. Among these
45 cases investigated for RET tyrosine kinase expression, there
were 20 with an identified PTC1 or -3 rearrangement, including
one tumour which showed both PTC1 and -3; 18 showed RET tyro-
sine kinase expression. The unexpected negative RET tyrosine
kinase in two cases may be the result of a lack of sensitivity.
Twenty-five cases lacked either a PTC1 or -3 rearrangement, 21
were negative for RET tyrosine kinase expression, while four were
positive. The positive RET tyrosine kinase in these four cases could
result from the presence of a RET rearrangement other than PTC1
or -3, for example those described by Fugazzola et al (1995) and
Klugbauer et al (1995, 1998). Overall agreement between the two
techniques was therefore present in 39 out of 45 cases (87%).
We have compared the frequency of detection of RET rearrange-
ment in formalin-fixed paraffin-embedded material with that from
fresh tissue, but due to availability of material were only able to do
that by comparing the frequency in different groups of tumours,
not in identical tumours (Table 3). Adequate RNA was available
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Table 2 Histology of post-Chernobyl thyroid carcinomas examined for mutation of various oncogenes
Type of material Fixed material only Frozen material
Total number of tumours 82 50
No. papillary carcinomas 80 48
No. not analysablea 19 3
No. analysed 61 45
Subtype of papillary carcinoma in the
tumours analysed
Solid/follicular 46 (75%) 32 (71%)
Classic or diffuse sclerosing variant 15 (25%) 11 (25%)
Insufficient to subclassify 0 2 (4%)
a Nucleic acid of inadequate quality.
196 354 561
H4 RET
breakpoint
RET/PTC1
HPRT
12345 7 6 8 9 1 01 11 21 31 41 5 A
B
697 790 997
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B
Figure 1 RET/PTC1 detection in Chernobyl papillary thyroid carcinomas.
(A) RNAs were amplified with RET/PTC1-specific primers, as indicated in the
schematic diagram, subjected to electrophoretic separation on a 2% agarose
gel, and hybridized with a RET probe covering its TK domain. Lane 1: a
negative control represented by RNA from the TPC cell line (a human
papillary carcinoma cell line spontaneously expressing a RET/PTC1
oncogene) subjected to PCR without previous reverse-transcription. Lane 2:
another negative control represented by normal thyroid RNA; lanes 3–14:
representative examples of RNAs from papillary thyroid carcinomas from the
Chernobyl area showing seven positive samples. Amplification of the RNAs
without previous reverse transcription gave negative results (data not
shown). Lane 15: a positive control represented by RNA extracted from the
TPC cell line. (B) The same RNAs were subjected to RT-PCR amplification
using HPRT (human phosphoribosyl transferase)-specific primers. The
products of the amplification were run on a 2% agarose gel and hybridized to
an HPRT-specific probe. This confirmed that the negative results were not
due to absence of amplifiable RNA
Figure 2 RET/PTC3 detection in Chernobyl papillary thyroid carcinomas.
(A) RNAs were amplified with RET/PTC3 specific primers, as indicated in the
schematic diagram, subjected to electrophoretic separation on a 2% agarose
gel, and hybridized with a RET probe covering its TK domain. Lanes 1–2: two
representative cases scored positive for RET/PTC3 expression. Lane 3: a
negative control represented by normal thyroid RNA. (B) The same RNAs
were subjected to RT-PCR amplification using HPRT (human phosphoribosyl
transferase)-specific primers. The products of the amplification were run on a
2% agarose gel and hybridized to an HPRT-specific probefrom paraffin sections of 61 tumours resected from 1990 to 1994.
Sixteen were positive for RET rearrangement (13 PTC1 and three
PTC3). Adequate RNA was available from fresh tissue from 45
cases resected in 1995–1996; these are the same group in which
RET TK expression was compared with RET rearrangement. Of
these 45 cases, 20 showed RET rearrangement, eight PTC1 and 13
PTC3 (one tumour had both rearrangements).
The type of RET rearrangement correlated with the morpho-
logical type of papillary carcinomas, with PTC3 being found more
commonly in those of solid/follicular morphology, and PTC1
found in the less common classic papillary and diffuse sclerosing
variant of papillary carcinoma (see Figure 3).
No mutations in any of the ras genes, exon 10 of the TSH
receptor or in exons 6, 7 or 8 of the p53 gene were identified in any
tumour (Table 4).
DISCUSSION
We present the results of a comprehensive study of a large series of
post-Chernobyl papillary carcinomas studying a range of different
types of oncogenes in a large series of tumours, and comparing
these findings to detailed morphology.
RET gene rearrangements have been reported in about one-third
of adult papillary carcinomas not known to be radiation related,
but were not found in any other type of thyroid carcinoma (Santoro
et al, 1992). One study of thyroid tumours in adult patients with 
a history of external radiation found that ret rearrangements
occurred in follicular adenomas as well as papillary carcinomas
(Bounacer et al, 1997). A more recent study, which reported find-
ings on children exposed to fallout from the Chernobyl accident
found that ret rearrangement was restricted to papillary carci-
nomas; no rearrangement of this gene was observed in follicular
tumours (Thomas et al, 1999). In the majority of studies of
tumours not known to be related to radiation exposure, ret
rearrangement has been found only in papillary carcinomas. In a
study of 21 cases of papillary carcinoma from children under 15 at
operation in England and Wales 47% showed expression of 
the RET oncogene suggesting the presence of a rearrangement
(Williams et al, 1996). The relative frequency of the two major
subtypes of ret rearrangement (PTC1 and -3) varies in studies
which report their incidence post-Chernobyl. In two small studies
of Chernobyl-related thyroid cancer, one with four cases with
rearrangement and one with nine, PTC3 was the commonest type
of RET rearrangement found (Fuggazola et al, 1995; Klugbauer et
al, 1995). In a larger study, 33 of 38 selected cancers from patients
under the age of 18 from Belarus showed a RET rearrangement, 22
of these were PTC3 (Nikiforov et al, 1997). In the most recent
reported study of 51 cases under 16 at operation, 25 papillary
carcinomas showed a ret rearrangement, with an almost equal
frequency of the two types of rearrangement (Smida et al, 1999).
We have found both PTC1 and -3 in these 106 cases, all under 15
at operation, but have also shown that the two commonest RET
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Table 3 Identification of PTC1 or -3 rearrangement of the ret oncogene from formalin-fixed, paraffin-embedded
and frozen material
Type of material Fixed material Frozen material
(cases operated 1990–1994) (cases operated 1995–1996)
No. papillary carcinomas 80 48
No. not analysablea 19 3
No. analysed 61 45
PTC1 13 7
PTC3 3 12
PTC1 and PTC3 0 1
Negative for PTC1 or -3 45 25
a RNA of inadequate quality.
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Table 4 Oncogene involvement in post- Chernobyl papillary carcinomas
No. studied No. positive No. negative % positive
ret rearrangement 106 36 70 34
ret TK expression 46 23 23 50
TSHR 57 0 57 0
p53 35 0 35 0
Ki 31 0 31 0
N 23 0 23 0
Ha 23 0 23 0
Rearrangement of the ret oncogene was assessed in two ways; by
identification of the PTC1 and PTC3 rearrangement and also by expression
of the 3¢ end of the c-ret gene in the absence of expression of the
extracellular domain. Exon 10 of the TSH receptor, exons 5, 6, 7 and 8 of the
p53 gene, together with codons 12, 13 and 61 of the ras oncogenes were
examined for mutation. Ret rearrangement was analysed on both frozen
(cases operated in 1995–96) and paraffin material (cases operated in
1990–4). Ret TK expression was carried out on frozen material only. TSHR
mutation was carried out on a subset of both paraffin and frozen material.
The remaining oncogenes were examined in paraffin specimens only.
Figure 3 Association of different ret rearrangements with morphological
subtypes of papillary carcinomarearrangements, PTC1 and -3, show an association with different
morphologies of papillary carcinoma, PTC1 being more common
in tumours with a classical or diffuse sclerosing phenotype and
PTC3 more common in papillary carcinomas with a solid/-
follicular phenotype (P < 0.001 c2 test), in agreement with and
extending the earlier conclusions of Nikiforov et al (1997) who
showed that papillary tumours with a solid architecture from
exposed children had a high prevalence of PTC3 rearrangement.
This correlation might be related to the level of RET TK expres-
sion in the two rearrangements, or to an influence of the gene to
which the RET TK is fused, or to an effect related to the reciprocal
breakpoint. However, transgenic mice which have a thyroid
targetted expression of the PTC1 or -3 rearrangement also show
the same association between morphology and expression of the
different  RET rearrangements, with PTC1 transgenic animals
showing tumours of classical papillary morphology (Jhiang et al,
1996; Santoro et al, 1996) and PTC3 transgenic mice showing
tumours of predominantly solid morphology (Powell et al, 1998).
The finding that the inappropriate expression of the same tyrosine
kinase in these animals results in an alteration of the morphology
of the tumours produced suggests a morphogenetic role for the
gene to which the RET tyrosine kinase is fused.
The differing frequencies of RET rearrangement found in the
series of cases which we analysed on paraffin and the series
analysed from frozen cannot be explained by differing frequencies
of papillary carcinomas with solid/follicular morphology within
the two series; 75% of the papillary carcinomas analysed were of
this morphology in the paraffin series and 71% in the frozen series.
The difference in the frequency of PTC3-positive tumours is more
likely to reflect either the technical difficulty of analysing paraffin
material or possibly a change in the molecular biology of post-
Chernobyl carcinoma with time; the paraffin series were from
patients operated in 1990–1994, and the frozen material was from
patients operated in 1995 and 1996. A recent study by Smida et al
(1999) using frozen samples only, suggests that the ratio of
PTC3:PTC1 drops with time post-Chernobyl. However, this report
does not provide detailed histological analysis, so we do not know
whether these changes correlate with changes in the morphology
of tumours studied in the two time periods. Other studies have
shown that PTC1 rearrangement is more common in papillary
carcinoma from adults with a radiation history (Bounacer et al,
1997), but whether this is related to age of patient at exposure to
radiation or the histological subtype of papillary carcinoma
warrants further investigation. Only one of our cases showed both
PTC1 and -3 rearrangement, contrasting with a recent study using
a similar technique (RT-PCR followed by Southern hybridization)
which found that multiple rearrangements were not infrequent in
papillary carcinomas in adults (Sugg et al, 1998).
TSH receptor pathway mutations are common in hyperfunc-
tioning follicular tumours, but have rarely been found in papillary
carcinomas (Challeton et al, 1995; Ohno et al, 1995; Parma et al,
1995; Waldman and Rabes, 1997). p53 mutations have been
largely confined to undifferentiated thyroid carcinomas (Ito et al,
1992). There have been two recent reports suggesting that
germline polymorphisms of the p53 gene in exon 6 and intron 6
may be found occasionally in the Belarussian population
(Hillebrandt et al, 1997; Smida et al, 1997); one study failed to
demonstrate oncogenic p53 mutations in post-Chernobyl papillary
carcinomas (Suchy et al, 1998), while another found them in only
6% (Nikiforov et al, 1996). Our findings therefore suggest that the
pattern of oncogene involvement in the Chernobyl-related cancers
correlates with the morphological type, and shows a similar
frequency to that found in studies of thyroid cancer generally.
The lack of any ras gene mutation needs discussion. Most
earlier studies used slot blot and mutation specific oligo-
nucleotide hybridization and found a significant proportion, up to
62%, of papillary carcinomas with a ras mutation (Suarez et al,
1990). The difference from our findings could be related to age,
environmental or genetic factors, or to the techniques used. One
study using Southern blotting and hybridization (Shi et al, 1991)
and another using PCR and direct sequencing (Manenti et al,
1994) failed to find any ras mutations in papillary carcinomas.
Slot blot techniques could be detecting mutations in tumour sub-
populations, while PCR and sequencing techniques may fail to
detect mutations because of the presence of excess stromal tissue.
Our techniques used careful microdissected tumour samples,
detected ras mutations in the expected proportion of pancreatic
and thyroid follicular carcinomas and reliably detected ras muta-
tions if they were present in more than 40% of the tumour cells
(data not shown). In agreement with our findings, Suchy et al
(1997) found no ras mutations in post-Chernobyl childhood
thyroid carcinomas. One previous study has suggested that Ki-ras
mutation in follicular carcinomas may be related to radiation
exposure (Wright et al, 1991) and another that it may occasionally
occur in radiation-associated papillary carcinomas (Challeton et
al, 1995). In a separate study of 26 UK childhood papillary carci-
nomas, we found no mutations in any of the three ras genes (data
not shown). It would therefore appear that ras is not involved in
childhood papillary carcinomas whether they are of radiation aeti-
ology or not. We conclude that in follicular carcinogenesis point
mutation in a ras gene can be an early event, as it has been identi-
fied in adenomas as well as carcinomas (Lemoine et al, 1989;
Suarez et al, 1990; Wright et al, 1991). In papillary carcinogen-
esis rearrangement of the RET gene is an early event, as immuno-
histochemistry shows RET gene overexpression in a proportion of
both small and large papillary carcinomas (Viglietto, 1995), and
there is no morphological evidence of any precursor lesion for
papillary carcinoma.
While papillary carcinomas are associated with RET rearrange-
ments and follicular carcinomas with ras mutations, in neither case
are these present in all tumours. Other point mutations, including
mutations in gsp, and TSHr have been found in follicular tumours
(Challeton et al, 1995; Parma et al, 1995; Russo et al, 1995). In
papillary tumours rearrangements of the trk oncogene have been
found in a small minority of cases (Grieco et al, 1992; Beimfohr 
et al, 1999), two further rearrangements of the RET oncogene 
have recently been defined in post-Chernobyl thyroid cancer
(Fugazzola et al, 1996; Klugbauer et al, 1998), and it is likely that
the majority, possibly the great majority of papillary carcinomas
are associated with a chromosome rearrangement. Among
mutagens radiation is particularly prone to give double-strand
DNA breaks leading to deletions and rearrangements
(Sankaranarayanan, 1991), lesions that form only a minority of
chemical mutagen-induced or naturally occurring mutations.
Irradiation of cultured thyroid tumour cells has been shown to be
capable of causing RET rearrangements (Ito et al, 1993).
We suggest that the restriction of the thyroid tumour increase so
far seen to one type of carcinoma is not related to the ability of
radiation to cause one specific mutation, but to the general ability
of radiation to induce gene rearrangements; those arrangements
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this case rearrangements that activate the RET or trk tyrosine
kinases can stimulate growth and lead to papillary carcinoma, the
particular type of thyroid carcinoma found. There is as yet no
convincing evidence that radiation is specifically linked to a
particular type of RET rearrangement, and different selection
factors for different RET rearrangements could operate at different
ages. The relative lack of follicular carcinomas may be linked to
the association of the early stages of follicular carcinogenesis with
point mutations rather than gene rearrangements, or to a longer
latent period, perhaps related to progression through an adenoma.
There is an interesting parallel with the situation in leukaemia,
where the main type linked with radiation exposure, chronic
myeloid leukaemia, is associated with an abnormal karyotype with
a 9:22 translocation in virtually every case, while in chronic
lymphatic leukaemia, not known to be related to exposure 
to radiation the majority of typical cases lack any detectable
karyotypic abnormality (Woessner et al, 1996).
Our findings show that there is no doubt that a major increase of
childhood thyroid carcinoma has occurred in the area around
Chernobyl, and that it is currently restricted to one type of differ-
entiated tumour. Molecular biology investigations correlate with
the morphology, and show that papillary carcinoma can be
regarded as especially associated with gene rearrangement while
follicular carcinoma is associated with point mutation. We suggest
that the current restriction of the increase to papillary carcinoma is
linked to the particular effectiveness of radiation in causing
doublestrand breaks and gene rearrangements.
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